David Busse1, Weifeng Tang2, Markus Scheerer3, Thomas Danne4, Torben Biester4, Viktor Sokolov5, David Boulton2, Joanna Parkinson1. 1. Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden. 2. Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Gaithersburg, MD, USA. 3. Diabetes Medical Department, AstraZeneca GmbH, Wedel, Germany. 4. AUF DER BULT, Children's and Youth Hospital, Hannover, Germany. 5. M&S Decisions, Moscow, Russia.
Abstract
AIMS: To quantitatively compare pharmacokinetics (PK) and the exposure-response (ER) relationship of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, between adolescents/young adults and adults with type 1 diabetes mellitus (T1DM). METHODS: Data from 2 clinical studies for dapagliflozin were analysed using a non-linear mixed-effects approach. The PK and the relationship between dapagliflozin exposure and response (24-hour urinary glucose excretion) were characterized. PK was evaluated using a 2-compartment model with first-order absorption while the exposure response-relationship was analysed using a sigmoidal maximal-effect model. The 24-hour median blood glucose, estimated glomerular filtration rate (eGFR), sex, age and body weight were evaluated as covariates. RESULTS: A 2-compartment model with first order absorption provided a reasonable fit to the dapagliflozin PK data. Body weight was found to be a significant covariate on dapagliflozin exposure. The ER relationship was best described by a sigmoidal maximal effect model with 24-hour median blood glucose and eGFR as significant covariates on maximal effect. In accordance with the observed data, model-predicted urinary glucose excretion response following 10 mg dapagliflozin dose was higher in the study in adolescents/young adults (138.0 g/24 h) compared to adults (70.5 g/24 h) with T1DM. This is linked to higher eGFR and 24-hour median blood glucose in this trial. CONCLUSIONS: Dapagliflozin PK and ER relationship were similar in the 2 analysed studies after accounting for covariate effects. These results suggest that no dose adjustment is required for adolescent patients with T1DM.
AIMS: To quantitatively compare pharmacokinetics (PK) and the exposure-response (ER) relationship of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, between adolescents/young adults and adults with type 1 diabetes mellitus (T1DM). METHODS: Data from 2 clinical studies for dapagliflozin were analysed using a non-linear mixed-effects approach. The PK and the relationship between dapagliflozin exposure and response (24-hour urinary glucose excretion) were characterized. PK was evaluated using a 2-compartment model with first-order absorption while the exposure response-relationship was analysed using a sigmoidal maximal-effect model. The 24-hour median blood glucose, estimated glomerular filtration rate (eGFR), sex, age and body weight were evaluated as covariates. RESULTS: A 2-compartment model with first order absorption provided a reasonable fit to the dapagliflozin PK data. Body weight was found to be a significant covariate on dapagliflozin exposure. The ER relationship was best described by a sigmoidal maximal effect model with 24-hour median blood glucose and eGFR as significant covariates on maximal effect. In accordance with the observed data, model-predicted urinary glucose excretion response following 10 mg dapagliflozin dose was higher in the study in adolescents/young adults (138.0 g/24 h) compared to adults (70.5 g/24 h) with T1DM. This is linked to higher eGFR and 24-hour median blood glucose in this trial. CONCLUSIONS:Dapagliflozin PK and ER relationship were similar in the 2 analysed studies after accounting for covariate effects. These results suggest that no dose adjustment is required for adolescent patients with T1DM.
Authors: Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane Journal: Diabetes Care Date: 2015-06 Impact factor: 19.112
Authors: Paresh Dandona; Chantal Mathieu; Moshe Phillip; Lars Hansen; Steven C Griffen; Diethelm Tschöpe; Fredrik Thorén; John Xu; Anna Maria Langkilde Journal: Lancet Diabetes Endocrinol Date: 2017-09-14 Impact factor: 32.069
Authors: Stephen Ph Alexander; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2017-12 Impact factor: 8.739
Authors: Chantal Mathieu; Paresh Dandona; Pieter Gillard; Peter Senior; Christoph Hasslacher; Eiichi Araki; Marcus Lind; Stephen C Bain; Serge Jabbour; Niki Arya; Lars Hansen; Fredrik Thorén; Anna Maria Langkilde Journal: Diabetes Care Date: 2018-07-19 Impact factor: 19.112
Authors: Songping Han; Deborah L Hagan; Joseph R Taylor; Li Xin; Wei Meng; Scott A Biller; John R Wetterau; William N Washburn; Jean M Whaley Journal: Diabetes Date: 2008-03-20 Impact factor: 9.461
Authors: Wei Meng; Bruce A Ellsworth; Alexandra A Nirschl; Peggy J McCann; Manorama Patel; Ravindar N Girotra; Gang Wu; Philip M Sher; Eamonn P Morrison; Scott A Biller; Robert Zahler; Prashant P Deshpande; Annie Pullockaran; Deborah L Hagan; Nathan Morgan; Joseph R Taylor; Mary T Obermeier; William G Humphreys; Ashish Khanna; Lorell Discenza; James G Robertson; Aiying Wang; Songping Han; John R Wetterau; Evan B Janovitz; Oliver P Flint; Jean M Whaley; William N Washburn Journal: J Med Chem Date: 2008-02-09 Impact factor: 7.446